Page 8 - Tim Boreham News Today

Imricor is a player in a global catheter ablation market worth $US5.5 billion and growing at a compound rate of just over 8% a year

Pharmaxis might be two clinical studies away from rehabilitation, reports Tim Boreham

Tim Boreham reports the world might soon be scrambling for helium, while also identifying three ASX-listed exposures

Tim Boreham digs deep into the evolving world of cancer diagnostics, highlighting the newly named Inoviq Ltd

Vaxxas is still unlisted, but worth highlighting as yet another Australian success story looks to be unfolding, reports Tim Boreham

Tim Boreham, with some help from Ausbil, lines up his small-cap favourites from the August reporting season in Australia

Telix Pharmaceuticals' prostate cancer imaging product Illucix is quickly conquering the USA, but management at the firm has (much) higher ambitions

Dedicated lung imaging pioneer 4D medical sees itself as a software company, with lots of future potential, including from the US military

A look into the prospects for Australian-listed auto stocks this reporting season

Micro-cap biotech Orthocell is aiming to emulate the successful growth story of Polynovo, nowadays capitalised at $1.1bn